Effect of Salvage Chemotherapy Before Donor Lymphocyte Infusion in Patients With Relapse After Allogeneic Hematologic Stem Cell Transplantation

ALADAĞ KARAKULAK E., GÖKER H., BÜYÜKAŞIK Y., DEMİROĞLU H.

TRANSPLANTATION PROCEEDINGS, vol.53, no.1, pp.391-395, 2021 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 53 Issue: 1
  • Publication Date: 2021
  • Doi Number: 10.1016/j.transproceed.2020.06.016
  • Journal Name: TRANSPLANTATION PROCEEDINGS
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CAB Abstracts, EMBASE, MEDLINE, Veterinary Science Database
  • Page Numbers: pp.391-395
  • Hacettepe University Affiliated: Yes

Abstract

Objectives. Allogeneic hematopoietic stem cell transplantation (AHSCT) is an important treatment option in hematologic malignancies. Relapse after AHSCT is an indicator of poor prognosis. These patients may be treated with donor lymphocyte infusion (DLI). The chemotherapy given before DLI increases the success of the treatment by reducing the burden of disease. The aim of this study is to investigate post-DLI graft vs host disease (GvHD) and survival based on the course of chemotherapy given before DLI.